Coronary revascularization strategies: From PCI versus CABG to an individualized approach
Main Article Content
Abstract
Background: Coronary revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) remains a cornerstone in the management of complex coronary artery disease, particularly in patients with left main coronary artery disease and multivessel disease. Major randomized trials, including SYNTAX, EXCEL, NOBLE, and FREEDOM, have provided substantial evidence comparing these two strategies; however, their findings indicate that no single approach is optimal for all patients.
Coronary revascularization strategies should therefore be individualized according to anatomical complexity, surgical risk, the feasibility of complete revascularization, comorbidities, age, left ventricular function, and, importantly, patient preferences. Decision-support tools such as the SYNTAX Score II 2020, STS score, and EuroSCORE II, together with physiological and intracoronary imaging modalities including FFR/iFFR and IVUS/OCT, as well as multidisciplinary Hear Team discussion, are increasingly important in guiding treatment decisions. Accordingly, this review aims to summarize contemporary evidence on PCI and CABG, identify key factors supporting individualized coronary revascularization, and discuss their applicability in clinical practice in Vietnam.
Methods: To provide a narrative review of randomized controlled trials, meta-analyses, and clinical practice guidelines published between 2019 and 2026, with a focus on: (1) short-and long-term outcomes of PCI versus CABG in clinically relevant patient subgroups; (2) the role of SYNTAX Score II 2020, STS/EuroSCORE II, FFR/iFR, and IVUS/OCT in guiding revascularization strategy; (3) the clinical relevance of complete revascularization and staged revascularization strategies; (4) the role of the Heart Team in treatment decision-making; and (5) the applicability of individualized revascularization principles in the Vietnamese healthcare setting.
Evidence: Major randomized trials have demonstrated that the choice between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) should be guided by individual anatomical characteristics and clinical risk. In appropriately selected patients undergoing coronary angiography, long-term mortality appears broadly comparable between PCI and CABG; however, PCI is associated with higher rates of spontaneous myocardial infarction (8% vs. 3%) and repeat revascularization (17% vs. 10%). Over long-term follow-up, CABG has been associated with a 30–40% reduction in the risk of myocardial infarction and a 50–60% reduction in the need for repeat revascularization. In patients with multivessel coronary artery disease, particularly those with diabetes mellitus or complex coronary anatomy, CABG provides greater protection against major cardiovascular events (10.9% vs. 16.3%) and reduces the need for long-term repeat revascularization (6.0% vs. 13.9%).
Contemporary revascularization decision-making should integrate the SYNTAX Score II 2020, STS/EuroSCORE II, the likelihood of achieving complete revascularization, physiological lesion assessment with FFR/iFR, intracoronary imaging with IVUS/OCT, and multidisciplinary Heart Team discussion. In Vietnam, complex PCI and CABG, as well as FFR/iFR and IVUS/OCT, are increasingly available at major cardiovascular centers. Nevertheless, access to these technologies, their integration into a multimodality decision-making strategy, treatment costs, and institutional expertise remain heterogeneous. Therefore, coronary revascularization strategies should be individualized according to each patient’s clinical and anatomical profile as well as the real-world capabilities of the treating institution.
Conclusion: No single revascularization strategy is optimal for all patients. The choice between PCI and CABG should be based on coronary anatomy, clinical risk, the feasibility of complete revascularization, comorbidities, and patient preferences. In the Vietnamese healthcare setting, treatment decisions should also take into account access to advanced technologies, treatment costs, adherence to long-term medical therapy, and institutional expertise. The Heart Team should remain central to the individualized selection of the optimal coronary revascularization strategy
Keywords
PCI, CABG, Left main coronary disease, Diabetes mellitus, Heart Team
Article Details
References
2. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. doi:10.1093/eurheartj/ehy394
3. Gaudino M, Antoniades C, Benedetto U, et al. Mechanisms, Consequences, and Prevention of Coronary Graft Failure. Circulation. 2017;136(18):1749-1764. doi:10.1161/CIRCULATIONAHA.117.027597
4. Stone GW, Kappetein AP, Sabik JF, et al. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019;381(19):1820-1830. doi:10.1056/NEJMoa1909406
5. Holm NR, Mäkikallio T, Lindsay MM, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. The Lancet. 2020;395(10219):191-199. doi:10.1016/S0140-6736(19)32972-1
6. Farkouh ME, Domanski M, Dangas GD, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes. J Am Coll Cardiol. 2019;73(6):629-638. doi:10.1016/j.jacc.2018.11.001
7. Gaudino M, Hameed I, Farkouh ME, et al. Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis. JAMA Intern Med. 2020;180(12):1638. doi:10.1001/jamainternmed.2020.4748
8. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191
9. Fearon WF, Zimmermann FM, De Bruyne B, et al. Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery. N Engl J Med. 2022;386(2):128-137. doi:10.1056/NEJMoa2112299
10. Ahmad Y, Howard JP, Arnold AD, et al. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41(34):3228-3235. doi:10.1093/eurheartj/ehaa135
11. Hennessy C, Henry J, Parameswaran G, Brameier D, Kharbanda R, Myerson S. Percutaneous Coronary Intervention vs. Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis. Cureus. Published online November 5, 2023. doi:10.7759/cureus.48297
12. Liu H, Li D, Gao C, et al. A Systematic Review and Meta-Analysis of 35,409 Patients Undergoing PCI versus CABG for Unprotected Left Main Coronary Artery Diseases. Rev Cardiovasc Med. 2024;25(8):282. doi:10.31083/j.rcm2508282
13. Hollman J, Johnson J. Left Main Revascularization in Perspective. Cardiology. 2023;148(4):293-295. doi:10.1159/000531068
14. Mills NL, Kristin Newby L, Zaman S, et al. Fifth Universal Definition of Myocardial Infarction (2026): On Behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Circulation. Published online August 27, 2026:CIR.0000000000001477. doi:10.1161/CIR.0000000000001477
15. Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. The Lancet. 2019;394(10206):1325-1334. doi:10.1016/S0140-6736(19)31997-X
16. Gaudino M, Angiolillo DJ, Di Franco A, et al. Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. J Am Heart Assoc. 2019;8(13):e013032. doi:10.1161/JAHA.119.013032
17. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae177
Similar Articles
- Cong Hieu Luong, Hoang Dinh Nguyen, Tho Tuan Anh Pham, Minh Bao Luan Tran, Mid-term Outcomes of Minimally Invasive Mitral Valve Repair Using Valve-Preserving Techniques for Severe Mitral Regurgitation due to Barlow’s Disease , The Vietnam Journal of Cardiovascular and Thoracic Surgery: Vol. 57
You may also start an advanced similarity search for this article.